Log In
BCIQ
Print this Print this
 

tanibirumab (TTAC0001)

  Manage Alerts
Collapse Summary General Information
Company PharmAbcine Inc.
DescriptionHuman mAb against vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1; VEGFR-2)
Molecular Target Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationBrain cancer
Indication DetailsTreat recurrent glioblastoma multiforme (GBM)
Regulatory Designation
Partner3SBio Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/18/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today